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The model of ethanol induced gastric lesions is useful in the evalu-
ation of gastric cytoprotection. We used it to measure cytoprotective
effects of two neuropeptides, Met-enkephalin (Peptid-M, LUPEX®)
and -melanocyte stimulating hormone (-MSH). Both peptides
exhibited significant and synergistic cytoprotective effects. The
best therapeutic efficacy was obtained with Met-enkephalin and -
MSH mixture 3–5 : 1. Significant cytoprotective action on ethanol
induced lesions was also observed by means of two thymus peptide
immunomodulators, Thymus Peptide C® and JAN 50®. Thymus
Peptide C® exhibited a more significant synergistic effect with
Met-enkephalin than JAN 50®. In addition to the cytoprotection of
rat gastric mucosa, Met-enkephalin also induced statistically sig-
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nificant and dose dependent Straub tail response versus control in
mice. Haloperidol, naloxone and Peptide-D antagonised its effects.
NMR spectrospic data supported molecular interaction of Met-
enkephalin and haloperidol, while neutralization of Met-enkepha-
lin induced Straub tail response by means of Peptide-D indicated
the presence of new non-opioid (naloxone independent) receptor
system containing Peptide-D sequence (calpastatin 201–205 aa).
Key words: Met-enkephalin, LUPEX®, -MSH, ethanol, gastric le-
sions, peptide-D, cytoprotection, Straub phenomenon, haloperidol,
NMR, Thymus Peptide C®, JAN 50®.
INTRODUCTION
Inflammatory diseases are still among great and unsolved problems of
modern medicine1 because of insufficient efficacy and many side effects of
antiinflammatory drugs.1 The most frequent side effects of antiinflammato-
ry drugs are gastric lesions.2,3
Ethanol induced gastric lesions constitute a useful model for the evalua-
tion of gastric cytoprotection. In this study, we have evaluated cytoprotecti-
ve effects of two neuropeptides, Met-enkephalin (Peptid-M, LUPEX®) and -
melanocyte stimulating hormone (-MSH). Both peptides exhibited signifi-
cant cytoprotective effects in several experimental models, including arthri-
tis, encephalomyelitis, graft versus host reaction, ischaemia and inflamma-
tory bowel disease.4–8
Synergistic action of Met-enkephalin and two thymus immunomodula-
ting peptides (Thymus Peptide C® and JAN 50®) was also investigated on
the model of ethanol induced gastric lesions in rat, since Peptid-M (LUPEX®)
represents the syntethic analogue of thymus Met-enkephalin.6
Additionally, in order to evaluate pharmacologically relevant interacti-
ons of Met-enkephalin, we evaluated the effects of its potential antagonists
(naloxone, Peptide-D, haloperidol) on Straub tail reaction and gastric cyto-
protection.9
MATERIAL AND METHODS
Experimental Animals
Gastric cytoprotection was evaluated in male Wistar rats, 150–200 g, bred by
the Department of Pharmacology, Zagreb University School of Medicine. The size of
the experimental groups was 8. Straub tail reaction was measured in Male albino
mice, NMRI, 25–30 g, bred by the Department of Pharmacology, Zagreb University
School of Medicine. The size of the experimental groups was 10.
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Measurement and Analysis of Cytoprotection
After sacrifice, hemorrhagic gastric area was assessed in mm2, using a digital
camera (JVC) and an image analysis software (SFORM, VAMS, Zagreb, Croatia).
Statistical analysis was made using Kruskal-Wallis and Mann-Whitney tests, with
statistical significance at p < 0.05.
Straub Tail Reaction and Scoring
W. Straub described this phenomenon, characterised by the sigmoid curving of
the tail over the back.9 The Straub tail reaction is believed to be produced by the
contraction of the sacrococcygeus dorsalis muscle. It is the prime model for opiod ef-
fects assessment in vivo. The Straub tail reaction is recorded every 5 minutes for 50
minutes after 0.9% NaCl or Met-enkephalin application.9 Arithmetic mean for each
animal is calculated and different groups are compared using the Analysis of Vari-
ance and Tukey HSD test. The tail reaction is scored9 as follows:
Substances
1. Met-enkephalin, i.e. Peptid-M (LUPEX®, Biofactor, Germany), Mr 573.
2. Peptide-D (IPPKY, Biofactor, Germany; Lot No. B-0158), > 97% purity, Mr 616.8.
3. Thymus Peptide C® (Biofactor, Germany).
4. JAN 50® (Biofactor, Germany).
5. Naloxone hydrochloride (Sigma, USA), > 99% purity.
6. Haloperodol (Sigma, USA), > 99% purity.
7. 0.9% NaCl
8. a-MSH (Commonwealth Biotechnologies, USA; Lot No. 010030399), >97% purity.
NMR Measurements
The 1H and 13C one- and two-dimensional NMR spectra of Met-enkephalin (LU-
PEX®) and haloperidol were recorded with a Varian Gemini 300 spectrometer, operat-
ing at 75.5 MHz for the 13C nucleus. All samples were measured from DMSO-d6 solu-
tion at 20 °C in 5 mm NMR tubes. Chemical shifts, in ppm, are referred to TMS.
Digital resolution in 1H NMR spectra was 0.20 Hz (Gemini 300), while in 13C NMR
spectra it was 0.63 Hz per point. The following spectra were recorded: broadband pro-
ton decoupling, gated proton decoupling, COSY-45, long-range (delayed) COSY-45,
NOESY and HETCOR. In all experiments, proton decoupling was performed by
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Waltz-16 modulation. Standard pulse sequences were used in two-dimensional experi-
ments. COSY-45 and delayed COSY-45 spectra were measured in the magnitude
mode, while NOESY spectra in the phase-sensitive mode. In COSY-45, delayed
COSY-45 and NOESY spectra, 1024 points in F2 dimension and 256 increments in F1
dimension, subsequently zero-filled to 1024 points, were used. Each increment was
obtained with 16 scans, 3000 Hz spectral width and a relaxation delay of 1 s. Thus,
the digital resolution was 5.9 Hz/point and 11.7 Hz/point in F2 and F1 dimensions,
respectively. The delayed COSY-45 spectra were measured with delay time, D3, of
0.25 s. The NOESY spectra were measured with several mixing times (0.45–1.2 s).
The HETCOR spectra were recorded with 2048 points in F2 dimension and 256 in-
crements in F1 dimension, zero-filled to 512 points. Increments were recorded with
180 scans, relaxation delay of 1 s and spectral width of 20000 Hz in F2 and 4500 Hz
in F1 dimensions. Corresponding digital resolution was 19.53 and 17.6 Hz/point in F2
and F1 dimensions, respectively. In broadband proton decoupled spectra of halope-
ridol and its mixtures with Met-enkephalin, carbon-fluorine spin-spin couplings
through one (ca. 251.8 Hz), two (21.7 Hz) and three (9.4 Hz) bonds were observed.
RESULTS
Evaluation of the protective effects of Met-enkephalin, -MSH and their
combination on the ethanol induced lesions of the gastric mucosa are pre-
sented in Tables I and III. It is evident that Met-enkephalin, -MSH and
combination Met-enkephalin + -MSH have a protective effect on gastric
mucosa (Table III). The best protective effect was obtained by the combina-
tion of Met-enkephalin and -MSH (Table III).
Similarly to the ethanol model, the administration of Met-enkephalin
(–30 min) exhibited also statistically significant cytoprotection in the stan-
dard cysteamine model, when 400 mg/kg cysteamine (i.e. 80 mg/mL aqua ad
iniectabilia) was administered to Wistar rats.6 The area of gastric lesions in
Met-enkephalin treated animals was significantly smaller (4.7  1.9 mm2,
p < 0.05) than in control animals (10.5  2.3 mm2, X  SEM).
Two immunoregulating thymus peptides (Thymus Peptide C® and JAN
50®) exhibited significant cytoprotective effects in the model of ethanol in-
duced gastric lesions (Table III). Statistically significant synergistic cytopro-
tective action with Met-enkephalin was more pronounced for Thymus Pep-
tide C®, while parallel administration of JAN 50® and Met-enkephalin had
less influence on the amount of cytoprotection already achieved by JAN 50®
(Table III).
Haloperidol abolished Met-enkephalin induced gastric cytoprotection
(Table IV).
Effects of Met-enkephalin, haloperidol, naloxone and Peptide-D on the
Straub tail reaction are presented in Table VI. Met-enkephalin has a statis-
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tically significant Straub tail inducing effect versus control. Haloperidol, na-
loxone and Peptide-D antagonised its effect.
DISCUSSION
Ethanol ingestion results in gastritis characterised10 by mucosal edema,
subepithelial haemorrhage, cellular exfoliation, and an inflammatory cell
infiltrate. The initial event in the pathogenesis of mucosal ulcerations is mi-
crovascular dysfunction.10,11 Exposure of the mucosa to ethanol (50–100%)
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TABLE I
Influence of Met-enkephalin (Peptid-M, LUPEX®), -MSH and two thymus
peptides (Thymus Peptide C® and JAN 50®) on 96% ethanol induced
gastricmucosal lesions – experimental design
Substance
Schedule
–1 h 0 h + 1 h
0.9% NaCl (control) application + ethanol 1mL/rat sacrifice
Met-enkephalin (10 mg/kg ip) application + ethanol 1mL/rat sacrifice
-MSH (3.3 mg/kg ip) application + ethanol 1mL/rat sacrifice
Thymus Peptide C® (50 mg/kg ip) application + ethanol 1mL/rat sacrifice
JAN 50® (100 mg/kg ip) application + ethanol 1mL/rat sacrifice
Met-enkephalin + -MSH application + ethanol 1mL/rat sacrifice
Met-enkephalin + Thymus Peptide C® application + ethanol 1mL/rat sacrifice
Met-enkephalin + JAN 50® application + ethanol 1mL/rat sacrifice
TABLE II
Influence of Met-enkephalin (Peptid-M, LUPEX®) and haloperidol on 96%
ethanol induced gastric mucosal lesions – experimental design
Substance
Schedule
–1 h 0 h +1 h
0.9% NaCl (control) application + ethanol 1mL/rat sacrifice
haloperidol (10 mg/kg ip) application + ethanol 1mL/rat sacrifice
Met-enkephalin (10 mg/kg ip) application + ethanol 1mL/rat sacrifice
Met-enkephalin + haloperidol application + ethanol 1mL/rat sacrifice
results in arteriolar vasodilatation, vascular congestion or stasis, haemocon-
centration, albumin leakage, and capillary damage.10 This is associated
with significant reductions in mucosal blood flow,10,12 and the extent of mu-
cosal injury is correlated with the magnitude of the blood flow reduction.12
Microvascular dysfunction is reminiscent of the vascular phase of acute in-
flammation.10–12 Also, neutrophils have been implicated in the mucosal in-
jury associated with ethanol-induced gastritis.13,14 In this context, the le-
sions resemble some human disease lesions, e.g. in inflammatory bowel
disease, gastritis, etc.
Effects of Met-enkephalin and -MSH are beneficial in the cytoprotec-
tive model investigated, especially their combination, which exhibits strong
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TABLE IV
Results for substances from Table II
Substance
Results
Area of lesions (mm2) Statistical significance
vs. controlmedian min max
0.9% NaCl (control) 385 373 432
Met-enkephalin 242 191 305 p < 0.05
haloperidol 430 342 460 p < 0.05
Met-enkephalin + haloperidol 449 420 497 p < 0.05
TABLE III
Results for substances from Table I
Substance
Results
Area of lesions (mm2) Statistial signifiance
vs. conrolmedian min max
0.9% NaCl (control) 360 294 473
Met-enkephalin 225 172 298 p < 0.05
-MSH 18 0 24 p < 0.001
Thymus Peptide C® 25 5 29 p < 0.01
JAN 50® 28 8 32 p < 0.01
Met-enkephalin + -MSH 0 0 4 p < 0.001
Met-enkephalin + Thymus Peptide C® 17 0 22 p < 0.01
Met-enkephalin + JAN 50® 31 0 46 p < 0.01
synergistic effects and almost completely protects the gastrointestinal mu-
cosa. This result has potential clinical application because Met-enkephalin
and -MSH are products of the same precursor molecules.15
Considering our results and the common pathways of peptide action, it
is reasonable to assume that both peptides should be applied together to
achieve optimal clinical and pharmacologic efficacy. The application of Met-
enkephalin + -MSH combination in severe autoimmune disease, which in
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TABLE V
Straub tail reaction – substances and experimental design
Substance
Schedule
–15 min 0 h
observation –
every 5 minutes
for 50 minutes
0.9% NaCl (control) 0.9% NaCl 0.9% NaCl observation
Met-enkephalin (10 mg/kg ip) 0.9% NaCl Met-enkephalin observation
haloperidol (10 mg/kg ip) haloperidol 0.9% NaCl observation
naloxone (10 mg/kg ip) naloxone 0.9% NaCl observation
Peptide-D (5 mg/kg ip) Peptide-D 0.9% NaCl observation
Met-enkephalin + haloperidol haloperidol Met-enkephalin observation
Met-enkephalin + naloxone naloxone Met-enkephalin observation
Met-enkephalin + Peptide-D Peptide-D Met-enkephalin observation
TABLE VI
Results for substances from Table V
Substance
Results
Straub tail reaction
(group mean  SEM)
Statistical signifiance
vs. control
0.9% NaCl (control) 0.33  0.05
Met-enkephalin 0.57  0.07 p < 0.05
haloperidol 0.28  0.04 n.s.
naloxone 0.35  0.05 n.s.
Peptide-D 0.35  0.09 n.s.
Met-enkephalin + haloperidol 0.25  0.04 n.s.
Met-enkephalin + naloxone 0.33  0.08 n.s.
Met-enkephalin + Peptide-D 0.34  0.06 n.s.
n.s. = not significant (p > 0.05).
addition to Met-enkephalin requires administration of a low/moderate cor-
ticosteroid dose, may enable tapping of the corticosteroids. In the context of
experimentally defined 5 : 1 ratio of Met-enkephalin : -MSH, the starting
dose for humans could be estimated at 5–10 mg Met-enkephalin + 1–2 mg
-MSH daily (5 times weekly for 4 weeks, then gradually reduced every four
weeks to once weekly). This is analogous to the extrapolation of animal (rat)
Met-enkephalin dose of other cytoprotective experimental models5 to effec-
tive human doses in clinical practice.4,18
Met-enkephalin and -MSH protect gastric mucosa in a different way
than non-steroidal antiinflammatory drugs (NSAID). NSAID have a nega-
tive effect on gastric mucosal integrity1–3,16,17 because of non-selective inhi-
bition of cyclooxigenase I. Even selective cyclooxigenase II inhibitors are not
side-effect free.3,16,17 Our preliminary investigation indicates that this is not
the case of the Met-enkephalin and -MSH combination. Effects of both pep-
tides include analgesia, antipiretic and antioxidant action,7,18 which opens a
possibility to achieve pharmacologic effects od both steroidal and non-stero-
idal antiinflammatory drugs, without most of their side-effects.
Met-enkephalin also exhibits synergistic effects on immunomodulating
thymus peptide fractions present in thymus glands of young calves, since
parallel administration of Thymus Peptide C® in ethanol induced gastric
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Figure 1. Neutralisation of Met-enkephalin (Peptid-M, LUPEX®) induced Straub tail
reaction by Peptide-D is comparable to naloxone effects.
lesions model (Table III) showed significant enhancement of the cyto-
protection. This effect was somewhat less pronounced for JAN 50® im-
munoregulating and correcting thymus peptide fraction of very young
calves. Since Met-enkephalin is also found in larger quantities in fetal thy-
mus, the synergistic action of both peptides with respect to the well known
Met-enkephalin immunomodulatory actions4–6,18 has a potential therapeutic
relevance.
According to our experimental results in the rat model, the estimated
human daily dose for Met-enkephalin + Thymus Peptide C® combination
would be 5–10 mg of Met-enkephalin + 25–50 mg Thymus Peptide C®. For
Met-enkephalin + JAN 50®, the starting daily dose would be 5–10 mg of
Met-enkephalin + 50–100 mg JAN 50®. Our experimental result is in agree-
ment with recent clinical pilot trials in which Thymus Peptide C® or JAN
50® were combined to Met-enkephalin and administered according to the
standard Met-enkephalin protocols (5 times weekly for 4 weeks, then gradu-
ally reduced every four weeks to once weekly; M. ^. Pe{i}, personal commu-
nication, [tambuk et al.18).
1H and 13C NMR study of haloperidol, Met-enkaphalin and their mix-
tures showed, through changes of chemical shifts and amid protons and car-
bonyl carbons, molecular interaction of both substances, which seems to be
responsible for the antagonisation of cytoprotective Met-enkephalin effects.
In this context, our data suggest that parallel administration of Met-enke-
phalin and haloperidol in human studies may be contraindicated, i.e. it
should be avoided prior to further comparative studies in mammals.
Interaction of Met-enkephalin with the dopamine system may be influ-
enced by molecular reactions of the peptide with dopamine antagonists (e.g.
haloperidol). Dopamine 2 receptor fragments (D2DR_HUMAN D, aa 298–
300, 403–405) correspond to the first 3 amino acids of the Met-enkephalin
complementary antagonist denoted Peptide-D.6 Peptide-D residues IPP bind
Met-enkaphalin residues YGG, and Peptide-D was shown to neutralise
Met-enkephalin effects in several models,6 including the Straub tail reac-
tion presented in Figure 1 and Table VI. Those effects were shown to be in-
dependent of the opioid system. Consequently, the neutralisation of Met-en-
kephalin induced Straub tail response by means of Peptide-D indicates the
presence of new non-opioid (naloxone independent) receptor system in the
region containing Peptide-D sequence (calpastatin 201–205 aa).
The results of our study indicate that the Met-enkephalin molecule, in
additon to different synergistic effects with ACTH system and thymus pep-
tides on cytoprotection during inflammation, also exhibits complex relation-
ships with several receptor classes at the molecular level. The pharmacolog-
ical importance of these relationships remains to be determined.
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Zaštitni u~inci Met-enkefalina pri ošte}enjima `elu~ane sluznice
izazvanima alkoholom
Paško Konjevoda, Nikola Štambuk, Dra`en Viki}-Topi}, Alenka Boban-Blagai},
Smiljka Viki}-Topi}, Vladimir Mrljak, Josip Pavan, Pero Ramadan
i Zdenko Bi|in
Etanolom izazvana o{te}enja `elu~ane sluznice koristan su eksperimentalni mo-
del za procjenu citoprotektivnih efekata razli~itih tvari. Spomenuti je model kori{ten
za procjenu citoprotektivnog efekta dva neuropeptida, Met-enkefalina (Peptid-M, LU-
PEX®) i melanocitnog stimuliraju}eg hormona  (-MSH). Oba neuropeptida izazvala
su znatne i sinergisti~ke citoprotektivne efekte. Najbolja terapijska efikasnost posti-
gnuta je pri omjeru doza Met-enkefalina i -MSH 3–5:1. Zna~ajna citoprotekcija u
etanolskom modelu opa`ena je i za dva timusna imunomoduliraju}a peptida, Timusni
Peptid C® i JAN 50®. Timusni Peptid C® pokazao je izrazitiji sinergisti~ki citopro-
tektivni efekt s Met-enkefalinom nego JAN 50®. Uz citoprotekciju na etanolskom mo-
delu {takora, Met-enkefalin je u mi{a izazvao pri visokim dozama statisti~ki zna~ajan
Straubov refleks repa. Haloperidol, naloxon i Peptid-D antagonizirali su spomenuti
refleks. NMR spektri Met-enkefalina, haloperidola i njihovih smjesa ukazali su na
molekulsku interakciju hormona i lijeka, a gotovo identi~ni nalazi neutralizacije
Straubova refleksa naloxonom i Peptidom-D potvr|uju da uz opioidne (naloxon-ovi-
sne) receptore postoji i interakcija Met-enkefalina s receptorskim sistemom koji sa-
dr`i sekvenciju Peptid-D (kalpastatin 201–205 aa).
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